Innovation in Biomanufacturing: What’s Ahead?
A panel moderated by Tom Ransohoff, Vice President and Principal Consultant, BioProcess Technology Consultants, will focus on the importance of innovation to our industry in a panel discussion in the BioProcess Theater located in the BioProcess Zone at BIO-2017. This informative panel, The Process of and Business Considerations for Innovation in Biomanufacturing: Supplier and End-User Perspectives is Wednesday, June 21st 11:00 a.m. – 12 p.m.
Due to the omnipresent demands to improve development speed, reduce costs and improve product quality, the biopharmaceutical industry has an ongoing need to evaluate and adopt new technologies in the manufacture and testing of our products. Nevertheless, in addition to the development costs and resources required to implement new technologies, there are significant regulatory, technical and timeline risks, which are amplified in the pharmaceutical industry and act as a brake on innovation. This panel will explore the business considerations for adopting new technologies and the processes used by industry leaders to ensure successful implementation, including perspectives from both suppliers and end-users.
This distinguished panel of industry leaders includes:
- Tom Ransohoff, Vice President, BioProcess Technology Consultants, Inc.
- John Bonham-Carter, Director, Repligen Corporation
- Bernard Huyghe, Senior Director, Pfizer
- Stewart McNaull, PhD, SVP, Business Development, KBI Biopharma, Inc.
- Todd Menkhaus, Co-founder, Nanopareil
Tom will be participating in the BIO Exhibit Hall activities Tuesday through Thursday. Please stop by the BPTC booth #1124 while at BIO 2017 to meet with Tom.